Clinical Trials Browser

Active not recruiting × Liver Neoplasms × durvalumab × Clear all

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03847428 2026-03-06

EMERALD-2

Phase 3 Active not recruiting

908 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05063565 2026-03-02

ROWAN

Phase 2 Active not recruiting

100 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT05883644 2026-02-18

SIERRA

Phase 3 Active not recruiting

111 enrolled

Gastrointestinal

Liver Neoplasms

NCT03937830 2026-02-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Phase 2 Active not recruiting

27 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03778957 2026-01-16

EMERALD-1

Phase 3 Active not recruiting

724 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05301842 2025-01-15

EMERALD-3

Phase 3 Active not recruiting

760 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Clinical Trials

EMERALD-Y90

EMERALD-2

ROWAN

SIERRA

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

EMERALD-1

EMERALD-3